NASDAQ:TPST Tempest Therapeutics (TPST) Stock Price, News & Analysis $0.62 -0.01 (-1.70%) Closing price 04:00 PM EasternExtended Trading$0.63 +0.00 (+0.45%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Tempest Therapeutics Stock (NASDAQ:TPST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tempest Therapeutics alerts:Sign Up Key Stats Today's Range$0.62▼$0.6750-Day Range$0.64▼$1.2152-Week Range$0.62▼$11.15Volume67,109 shsAverage Volume947,902 shsMarket Capitalization$10.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue. Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). The company has evaluated TPST-1120 as a monotherapy and in combination with immune checkpoint inhibitors for advanced solid tumors, including hepatocellular carcinoma. Tempest has also developed additional early-stage oncology programs, including TPST-1495, an investigational small-molecule inhibitor of cyclooxygenase enzymes. Founded in 2018 and headquartered in the United States, Tempest advances its programs through clinical studies conducted in collaboration with medical centers and research partners. Its activities are primarily focused on the development of therapies for patients with advanced cancers rather than on commercialized products. Stephen Brady has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Tempest Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreTPST MarketRank™: 0.71912454403 of 5 starsTempest Therapeutics scored higher than 14% of companies evaluated by MarketBeat, and ranked 839th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingTempest Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageTempest Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Tempest Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tempest Therapeutics are expected to decrease in the coming year, from ($0.83) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tempest Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tempest Therapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTempest Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tempest Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.65% of the float of Tempest Therapeutics has been sold short.Short Interest Ratio / Days to CoverTempest Therapeutics has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempest Therapeutics has recently increased by 73.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTempest Therapeutics does not currently pay a dividend.Dividend GrowthTempest Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.20 News SentimentTempest Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tempest Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for TPST on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders36.20% of the stock of Tempest Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions22.52% of the stock of Tempest Therapeutics is held by institutions.Read more about Tempest Therapeutics' insider trading history. Receive TPST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TPST Stock News HeadlinesTempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets ExpertiseOctober 14 at 8:00 AM | globenewswire.comTempest Therapeutics (NASDAQ:TPST) Upgraded to Sell at Wall Street ZenOctober 10, 2026 | americanbankingnews.comUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares still trade under 1 dollar. It just signed the largest transaction in its history, a new gold streaming deal backed by a strategic relationship with a major mining investment firm. A well-known sector financier has invested his own money and joins the CEO in an exclusive interview breaking down the full story.October 16 at 1:00 AM | Digest Publishing (Ad)Tempest Therapeutics consensus price target decreased by 36.36% to $7.14October 2, 2026 | msn.comTempest Appoints Global Finance Leader Nancy Freda-Smith to Board of DirectorsSeptember 23, 2026 | globenewswire.comTempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T PlatformSeptember 16, 2026 | finanznachrichten.deWhy Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving PremarketSeptember 16, 2026 | benzinga.comTempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64%September 16, 2026 | rttnews.comSee More Headlines TPST Stock Analysis - Frequently Asked Questions How have TPST shares performed this year? Tempest Therapeutics' stock was trading at $2.87 on January 1st, 2026. Since then, TPST shares have decreased by 78.0% and is now trading at $0.6310. How were Tempest Therapeutics' earnings last quarter? Tempest Therapeutics, Inc. (NASDAQ:TPST) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.04. When did Tempest Therapeutics' stock split? Tempest Therapeutics's stock reverse split on Friday, June 25th 2021.The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Tempest Therapeutics? Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tempest Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tempest Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Intel (INTC), Palantir Technologies (PLTR), Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST). Company Calendar Last Earnings8/13/2026Today10/16/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 4 days ago, TPST's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TPST CIK1544227 Webwww.tempesttx.com Phone415-798-8589FaxN/AEmployees4Year Founded2012Profitability EPS (Trailing Twelve Months)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-576.56% Return on Assets-134.99% Debt Debt-to-Equity RatioN/A Current Ratio0.38 Quick Ratio0.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book0.46Miscellaneous Outstanding Shares16,890,000Free Float10,776,000Market Cap$10.54 million OptionableNo Data Beta-1.73 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:TPST) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredNobody is talking about this…After the Dot-Com Bubble burst in March 2000, the Nasdaq fell 78% over the following decade. But gold staged a...Golden Portfolio | SponsoredWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured ...Crypto 101 Media | SponsoredTrump’s Dollar ResetA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TPST Stock Alerts